JP2019529455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529455A5 JP2019529455A5 JP2019515849A JP2019515849A JP2019529455A5 JP 2019529455 A5 JP2019529455 A5 JP 2019529455A5 JP 2019515849 A JP2019515849 A JP 2019515849A JP 2019515849 A JP2019515849 A JP 2019515849A JP 2019529455 A5 JP2019529455 A5 JP 2019529455A5
- Authority
- JP
- Japan
- Prior art keywords
- depot
- agents
- composite
- hydrogel
- hydrolyzable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002131 composite material Substances 0.000 claims 30
- 239000000017 hydrogel Substances 0.000 claims 21
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- -1 PDGFRβ blocker Substances 0.000 claims 17
- 239000002245 particle Substances 0.000 claims 16
- 239000002243 precursor Substances 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- 239000002202 Polyethylene glycol Substances 0.000 claims 12
- 229920001223 polyethylene glycol Polymers 0.000 claims 12
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 12
- 229960002930 sirolimus Drugs 0.000 claims 12
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 12
- 239000011159 matrix material Substances 0.000 claims 11
- 229920000954 Polyglycolide Polymers 0.000 claims 9
- 239000004633 polyglycolic acid Substances 0.000 claims 9
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 8
- 229950008835 neratinib Drugs 0.000 claims 8
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 8
- 150000003180 prostaglandins Chemical class 0.000 claims 8
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 6
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 6
- 208000001344 Macular Edema Diseases 0.000 claims 6
- 238000013270 controlled release Methods 0.000 claims 6
- 201000010206 cystoid macular edema Diseases 0.000 claims 6
- 201000011190 diabetic macular edema Diseases 0.000 claims 6
- 239000000463 material Substances 0.000 claims 6
- 208000030533 eye disease Diseases 0.000 claims 5
- MDPMAXSABUPRJI-UHFFFAOYSA-N 2-chloro-3-(1-cyanocyclopropyl)-n-[5-[[2-(cyclopropanecarbonylamino)-[1,3]thiazolo[5,4-b]pyridin-5-yl]oxy]-2-fluorophenyl]benzamide Chemical compound C1=C(NC(=O)C=2C(=C(C=CC=2)C2(CC2)C#N)Cl)C(F)=CC=C1OC(N=C1S2)=CC=C1N=C2NC(=O)C1CC1 MDPMAXSABUPRJI-UHFFFAOYSA-N 0.000 claims 4
- SRSGVKWWVXWSJT-ATVHPVEESA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 SRSGVKWWVXWSJT-ATVHPVEESA-N 0.000 claims 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 4
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 4
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 4
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 4
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 4
- 229930182558 Sterol Natural products 0.000 claims 4
- 239000003819 Toceranib Substances 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 4
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 4
- 229940035676 analgesics Drugs 0.000 claims 4
- 239000000730 antalgic agent Substances 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 229960005475 antiinfective agent Drugs 0.000 claims 4
- 239000004599 antimicrobial Substances 0.000 claims 4
- 229960003005 axitinib Drugs 0.000 claims 4
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 4
- 229960002584 gefitinib Drugs 0.000 claims 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 4
- 229960002411 imatinib Drugs 0.000 claims 4
- 229960004891 lapatinib Drugs 0.000 claims 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 4
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 4
- 235000019136 lipoic acid Nutrition 0.000 claims 4
- 229950003968 motesanib Drugs 0.000 claims 4
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 claims 4
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 4
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims 4
- 229960001002 nepafenac Drugs 0.000 claims 4
- 229960004378 nintedanib Drugs 0.000 claims 4
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 4
- 229960000639 pazopanib Drugs 0.000 claims 4
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 4
- 229960003787 sorafenib Drugs 0.000 claims 4
- 150000003432 sterols Chemical class 0.000 claims 4
- 235000003702 sterols Nutrition 0.000 claims 4
- 229960002663 thioctic acid Drugs 0.000 claims 4
- 229960005048 toceranib Drugs 0.000 claims 4
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical class CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 4
- 229960002368 travoprost Drugs 0.000 claims 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 4
- 208000002177 Cataract Diseases 0.000 claims 3
- 208000002691 Choroiditis Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 208000031354 Hyphema Diseases 0.000 claims 3
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 claims 3
- 208000003971 Posterior uveitis Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 210000002159 anterior chamber Anatomy 0.000 claims 3
- 210000001742 aqueous humor Anatomy 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 238000004132 cross linking Methods 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000007062 hydrolysis Effects 0.000 claims 3
- 238000006460 hydrolysis reaction Methods 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 231100000252 nontoxic Toxicity 0.000 claims 3
- 230000003000 nontoxic effect Effects 0.000 claims 3
- 239000004626 polylactic acid Substances 0.000 claims 3
- 201000010041 presbyopia Diseases 0.000 claims 3
- 210000001957 retinal vein Anatomy 0.000 claims 3
- 239000004698 Polyethylene Substances 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 229920000573 polyethylene Polymers 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022064398A JP7486539B2 (ja) | 2016-09-23 | 2022-04-08 | 前房内薬物送達デポ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398985P | 2016-09-23 | 2016-09-23 | |
| US62/398,985 | 2016-09-23 | ||
| PCT/US2017/053271 WO2018058048A1 (en) | 2016-09-23 | 2017-09-25 | Intracameral drug delivery depots |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022064398A Division JP7486539B2 (ja) | 2016-09-23 | 2022-04-08 | 前房内薬物送達デポ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529455A JP2019529455A (ja) | 2019-10-17 |
| JP2019529455A5 true JP2019529455A5 (enExample) | 2020-11-12 |
| JP7430529B2 JP7430529B2 (ja) | 2024-02-13 |
Family
ID=60022215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515849A Active JP7430529B2 (ja) | 2016-09-23 | 2017-09-25 | 前房内薬物送達デポ |
| JP2022064398A Active JP7486539B2 (ja) | 2016-09-23 | 2022-04-08 | 前房内薬物送達デポ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022064398A Active JP7486539B2 (ja) | 2016-09-23 | 2022-04-08 | 前房内薬物送達デポ |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US12171869B2 (enExample) |
| EP (2) | EP3515406B1 (enExample) |
| JP (2) | JP7430529B2 (enExample) |
| KR (3) | KR102814241B1 (enExample) |
| CN (1) | CN109982683A (enExample) |
| AU (1) | AU2017331444B2 (enExample) |
| DK (1) | DK3515406T3 (enExample) |
| ES (1) | ES2989941T3 (enExample) |
| IL (1) | IL265421B2 (enExample) |
| WO (1) | WO2018058048A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017062770A1 (en) | 2015-10-08 | 2017-04-13 | Silverberg Noah | Punctal plug and bioadhesives |
| AU2017331444B2 (en) * | 2016-09-23 | 2023-08-17 | Incept, Llc | Intracameral drug delivery depots |
| CA3133172A1 (en) * | 2019-03-13 | 2020-09-17 | Susmita Bose | Enzyme-degradable hydrogel for delivery of a payload |
| CN113766912A (zh) * | 2019-04-25 | 2021-12-07 | 视觉治疗股份有限公司 | 用于递送麻醉剂的小管内水凝胶插入物 |
| US20200337989A1 (en) * | 2019-04-25 | 2020-10-29 | Ocular Therapeutix, Inc. | Ocular hydrogel tyrosine kinase inhibitor implants |
| WO2020219892A1 (en) * | 2019-04-25 | 2020-10-29 | Ocular Therapeutix, Inc. | Hydrogel implants for lowering intraocular pressure |
| WO2021158968A1 (en) * | 2020-02-06 | 2021-08-12 | Ocular Therapeutix, Inc. | Compositions and methods for treating ocular diseases |
| PT3884929T (pt) | 2020-03-25 | 2023-08-09 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor da tirosina cinase |
| CA3177005A1 (en) | 2020-04-27 | 2021-11-04 | Michael Goldstein | Methods of treating allergic conjunctivitis |
| BR112023000669A2 (pt) * | 2020-07-16 | 2023-04-25 | Ocular Therapeutix Inc | Inserto ocular contendo um glicocorticoide |
| KR102893953B1 (ko) * | 2020-09-24 | 2025-12-02 | 오큘라 테라퓨틱스, 인코포레이티드 | 하이드로겔 및 사이클로스포린을 포함하는 지속 방출 생분해성 소관내 삽입체 |
| JP2023542939A (ja) * | 2020-09-24 | 2023-10-12 | オキュラ セラピューティクス，インコーポレイテッド | ヒドロゲル及び活性薬剤を含む徐放性生分解性小管内挿入物 |
| EP4346720A4 (en) * | 2021-05-28 | 2025-01-01 | Sight Sciences, Inc. | INTRAOCULAR DEVICES, SYSTEMS AND METHODS |
| CN114748436B (zh) * | 2022-05-30 | 2023-05-16 | 迪沙药业集团有限公司 | 一种硝苯地平组合物及其制备方法 |
| JP2025526731A (ja) * | 2022-08-12 | 2025-08-15 | オキュラ セラピューティクス，インコーポレイテッド | 持続的薬物送達のためのオルガノゲル、その調製及び使用の方法 |
| CN115337453A (zh) * | 2022-08-15 | 2022-11-15 | 珠海肤原生物科技有限公司 | 一种载有2-氧杂环庚烷酮的均聚物微球的医用无菌胶原蛋白产品的制备 |
| WO2024191453A1 (en) * | 2023-03-10 | 2024-09-19 | Clearstream Technologies Limited | Radiation spacer hydrogels, methods of forming, and methods of use |
| AU2024251447A1 (en) | 2023-04-11 | 2025-08-21 | Ocular Therapeutix, Inc. | Ocular implant comprising axitinib polymorph iv |
| WO2025255203A1 (en) * | 2024-06-06 | 2025-12-11 | Ocular Therapeutix, Inc. | Compositions and methods for treating ocular diseases |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3640741A (en) | 1970-02-24 | 1972-02-08 | Hollister Inc | Composition containing gel |
| US3865108A (en) | 1971-05-17 | 1975-02-11 | Ortho Pharma Corp | Expandable drug delivery device |
| US4002173A (en) | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
| DE2437629C3 (de) | 1974-08-05 | 1978-09-21 | Basf Ag, 6700 Ludwigshafen | Verfahren zur Herstellung von unlöslichen in Wasser nur wenig quellbaren Polymerisaten von N-Vinyllactamen |
| US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US4207893A (en) | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
| US4741872A (en) | 1986-05-16 | 1988-05-03 | The University Of Kentucky Research Foundation | Preparation of biodegradable microspheres useful as carriers for macromolecules |
| US5160745A (en) | 1986-05-16 | 1992-11-03 | The University Of Kentucky Research Foundation | Biodegradable microspheres as a carrier for macromolecules |
| IL82834A (en) | 1987-06-09 | 1990-11-05 | Yissum Res Dev Co | Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US5304595A (en) | 1988-11-21 | 1994-04-19 | Collagen Corporation | Collagen-polymer conjugates |
| IL90193A (en) | 1989-05-04 | 1993-02-21 | Biomedical Polymers Int | Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
| FR2657018A1 (fr) | 1990-01-12 | 1991-07-19 | Merck Sharp & Dohme | Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation. |
| US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US6371975B2 (en) | 1998-11-06 | 2002-04-16 | Neomend, Inc. | Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers |
| EP1027016A4 (en) | 1997-10-27 | 2006-03-08 | Univ California | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REFERRING RETINAL RIPPLE |
| US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
| US6958212B1 (en) | 1999-02-01 | 2005-10-25 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| US20050049578A1 (en) | 2000-04-14 | 2005-03-03 | Hosheng Tu | Implantable ocular pump to reduce intraocular pressure |
| AU2002236495B2 (en) | 2000-11-29 | 2006-05-11 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| MXPA03007665A (es) | 2001-02-26 | 2004-03-16 | Univ Duke | Polimeros dendriticos novedosos y sus usos biomedicos. |
| US6913765B2 (en) | 2001-03-21 | 2005-07-05 | Scimed Life Systems, Inc. | Controlling resorption of bioresorbable medical implant material |
| US20040131582A1 (en) | 2002-02-26 | 2004-07-08 | Grinstaff Mark W. | Novel dendritic polymers and their biomedical uses |
| US20040024345A1 (en) | 2002-04-19 | 2004-02-05 | Morteza Gharib | Glaucoma implant with valveless flow bias |
| US7351430B2 (en) | 2002-11-06 | 2008-04-01 | Uluru Inc. | Shape-retentive hydrogel particle aggregates and their uses |
| US20040137059A1 (en) | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
| US7129210B2 (en) | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
| US20050244458A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| WO2006031358A2 (en) | 2004-08-13 | 2006-03-23 | Hyperbranch Medical Technology, Inc. | Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses |
| WO2006031388A2 (en) | 2004-08-20 | 2006-03-23 | Hyperbranch Medical Technology, Inc. | Dentritic polymers, crosslinked gels, and their uses in orthopedic applications |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| WO2007001926A2 (en) | 2005-06-24 | 2007-01-04 | Hyperbranch Medical Technology, Inc. | Low-swelling hydrogel sealants for wound repair |
| WO2007005249A2 (en) | 2005-06-29 | 2007-01-11 | Hyperbranch Medical Technology, Inc. | Nanoparticles and dendritic-polymer-based hydrogels comprising them |
| US9173773B2 (en) * | 2006-06-21 | 2015-11-03 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
| US9125807B2 (en) | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
| JP5890182B2 (ja) * | 2009-02-12 | 2016-03-22 | インセプト エルエルシー | ヒドロゲルプラグによる薬物送達 |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| US8895508B2 (en) | 2009-07-24 | 2014-11-25 | Yasuhiki Tabata | Methods for corneal endothelial proliferation using bFGF sustained-release gelatin hydrogel particles |
| US8176360B2 (en) | 2009-08-11 | 2012-05-08 | Texas Memory Systems, Inc. | Method and apparatus for addressing actual or predicted failures in a FLASH-based storage system |
| CA2782899C (en) | 2009-12-15 | 2019-06-11 | Incept, Llc | Implants and biodegradable fiducial markers |
| US8647659B2 (en) | 2010-01-22 | 2014-02-11 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| CA2791278C (en) | 2010-02-25 | 2015-11-24 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| CN102905688B (zh) | 2010-04-06 | 2015-11-25 | 阿勒根公司 | 用于前房内药物递送的缓释储库式植入物 |
| US8961501B2 (en) | 2010-09-17 | 2015-02-24 | Incept, Llc | Method for applying flowable hydrogels to a cornea |
| US10226417B2 (en) * | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
| US9205150B2 (en) | 2011-12-05 | 2015-12-08 | Incept, Llc | Medical organogel processes and compositions |
| WO2014120866A1 (en) | 2013-01-31 | 2014-08-07 | Icon Bioscience, Inc. | Sustained release formulations for the treatment of intraocular pressure or glaucoma |
| ES2930433T3 (es) * | 2013-03-05 | 2022-12-12 | Univ Pittsburgh Commonwealth Sys Higher Education | Hidrogel termosensible que contiene micropartículas de polímero para la administración ocular no invasiva de fármaco |
| TWI631961B (zh) | 2013-03-15 | 2018-08-11 | 美商歐樂根公司 | 含有前列醯胺之眼內植入物 |
| ES2834964T3 (es) | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
| EP3076948B1 (en) | 2013-12-06 | 2020-11-18 | Allergan, Inc. | Intracameral implant for treatment of an ocular condition |
| CN107205922A (zh) | 2014-12-10 | 2017-09-26 | 因赛普特有限责任公司 | 水凝胶药物递送植入物 |
| CA3006303C (en) | 2015-11-25 | 2023-11-14 | Incept, Llc | Shape changing drug delivery devices and methods |
| AU2017331444B2 (en) | 2016-09-23 | 2023-08-17 | Incept, Llc | Intracameral drug delivery depots |
-
2017
- 2017-09-25 AU AU2017331444A patent/AU2017331444B2/en active Active
- 2017-09-25 DK DK17780606.4T patent/DK3515406T3/da active
- 2017-09-25 KR KR1020247011510A patent/KR102814241B1/ko active Active
- 2017-09-25 KR KR1020237011914A patent/KR20230053707A/ko not_active Ceased
- 2017-09-25 US US15/714,633 patent/US12171869B2/en active Active
- 2017-09-25 WO PCT/US2017/053271 patent/WO2018058048A1/en not_active Ceased
- 2017-09-25 CN CN201780072266.9A patent/CN109982683A/zh active Pending
- 2017-09-25 JP JP2019515849A patent/JP7430529B2/ja active Active
- 2017-09-25 IL IL265421A patent/IL265421B2/en unknown
- 2017-09-25 EP EP17780606.4A patent/EP3515406B1/en active Active
- 2017-09-25 EP EP23154758.9A patent/EP4197527A1/en active Pending
- 2017-09-25 KR KR1020197011614A patent/KR102520771B1/ko active Active
- 2017-09-25 ES ES17780606T patent/ES2989941T3/es active Active
-
2022
- 2022-04-08 JP JP2022064398A patent/JP7486539B2/ja active Active
- 2022-08-18 US US17/890,997 patent/US20220401356A1/en not_active Abandoned
-
2024
- 2024-11-11 US US18/943,498 patent/US20250144012A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kolawole et al. | In situ gelling drug delivery systems for topical drug delivery | |
| Bengani et al. | Steroid-eluting contact lenses for corneal and intraocular inflammation | |
| Shah et al. | Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy | |
| Schopf et al. | Topical ocular drug delivery to the back of the eye by mucus-penetrating particles | |
| Coursey et al. | Dexamethasone nanowafer as an effective therapy for dry eye disease | |
| JP6882186B2 (ja) | スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法 | |
| US20240082150A1 (en) | Ocular compositions | |
| JP6511401B2 (ja) | 持続型薬物送達インプラント | |
| JP7026507B2 (ja) | 眼において薬物徐放を達成する方法及び生体適合性組成物 | |
| Liu et al. | Changes in aqueous oxidative stress, prostaglandins, and cytokines: comparisons of low-energy femtosecond laser–assisted cataract surgery versus conventional phacoemulsification | |
| Donnenfeld et al. | Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study | |
| JP2010533225A5 (enExample) | ||
| JP2018515529A (ja) | ハイドロゲルからの薬物送達 | |
| Sahu et al. | Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification | |
| JP2023547607A (ja) | 活性薬剤を含む眼内インプラント | |
| Park et al. | Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles | |
| WO2015135306A1 (zh) | 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物 | |
| JP2021059554A (ja) | 増殖性硝子体網膜症用メトトレキサート | |
| CN115066232A (zh) | 用于治疗眼病的组合物和方法 | |
| CA2830555A1 (en) | Intraocular drug delivery device and associated methods | |
| KR20240156416A (ko) | 눈의 병태 치료를 위한 지속적 투여 요법 | |
| Al Zamil | Short-term safety and efficacy of intravitreal 0.7-mg dexamethasone implants for pseudophakic cystoid macular edema | |
| Chennamaneni et al. | Pharmacokinetics and Efficacy of Bioerodible Dexamethasone Implant in Concanavalin A-induced Uveitic Cataract Rabbit Model: Chennamaneni et al. | |
| Shin et al. | Biodegradable intrascleral implant of triamcinolone acetonide in experimental uveitis | |
| JP2020518626A (ja) | 加齢黄斑変性による地図状萎縮に対し使用するためのブリモニジンおよび臨床試験デザイン |